Literature DB >> 8346259

Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.

H G Göttlinger1, T Dorfman, E A Cohen, W A Haseltine.   

Abstract

The Vpu protein of human immunodeficiency virus type 1 facilitates the release of virus particles from the surface of infected cells. The ability of the Vpu protein to facilitate release of Gag proteins from retroviruses that lack a Vpu-like protein was examined. The results of these experiments show that Vpu significantly increases the release of the Gag proteins of human immunodeficiency virus type 2, visna virus, and Moloney murine leukemia virus from HeLa cells. The results indicate that Vpu-mediated enhancement of particle release requires neither amino-terminal myristoylation of the Gag precursor nor cleavage of the Gag precursor by the viral protease. The results raise the possibility that Vpu modifies a cellular pathway common to the release of all retroviruses from the cell surface.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346259      PMCID: PMC47141          DOI: 10.1073/pnas.90.15.7381

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export.

Authors:  X J Yao; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

4.  Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.

Authors:  R L Willey; F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs.

Authors:  S Schwartz; B K Felber; E M Fenyö; G N Pavlakis
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Equine infectious anemia virus gag and pol genes: relatedness to visna and AIDS virus.

Authors:  R M Stephens; J W Casey; N R Rice
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

7.  Transport and assembly of gag proteins into Moloney murine leukemia virus.

Authors:  M Hansen; L Jelinek; S Whiting; E Barklis
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  Brefeldin A inhibits the processing and secretion of envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  R Pal; S Mumbauer; G M Hoke; A Takatsuki; M G Sarngadharan
Journal:  AIDS Res Hum Retroviruses       Date:  1991-08       Impact factor: 2.205

9.  Isolation of replication-competent molecular clones of visna virus.

Authors:  K A Staskus; E F Retzel; E D Lewis; J L Silsby; S St Cyr; J M Rank; S W Wietgrefe; A T Haase; R Cook; D Fast
Journal:  Virology       Date:  1991-03       Impact factor: 3.616

10.  Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.

Authors:  H Schätzl; H R Gelderblom; H Nitschko; K von der Helm
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

View more
  107 in total

1.  vpu transmembrane peptide structure obtained by site-specific fourier transform infrared dichroism and global molecular dynamics searching.

Authors:  A Kukol; I T Arkin
Journal:  Biophys J       Date:  1999-09       Impact factor: 4.033

2.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation.

Authors:  A Deora; L Ratner
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 4.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.

Authors:  Abdul A Waheed; Maya Swiderski; Ali Khan; Ariana Gitzen; Ahlam Majadly; Eric O Freed
Journal:  J Biol Chem       Date:  2020-04-14       Impact factor: 5.157

6.  A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.

Authors:  Gajendra W Suryawanshi; Alexander Hoffmann
Journal:  J Theor Biol       Date:  2015-09-16       Impact factor: 2.691

7.  The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes.

Authors:  Satoshi Komoto; Shoutaro Tsuji; Madiha S Ibrahim; Yong-Gang Li; Jiranan Warachit; Koki Taniguchi; Kazuyoshi Ikuta
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment.

Authors:  Anjali Joshi; Sherimay D Ablan; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.